Cancer clinical trials in the region Bourgogne-Franche-Comté
152 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
Targeted therapy
Systemic Treatment-Naive
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
None
Systemic Treatment-Naive
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
EGFR
None
Chemotherapy
Radiotherapy
AstraZeneca
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
ALK
None
Systemic Treatment-Naive
Surgery
Hoffmann-La Roche
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
ALK
EGFR
Bristol-Myers Squibb
Early Access
Lung cancer
SCLC (Small Cell Lung Cancer)
Localized
Locally Advanced
None
Chemotherapy
Radiotherapy
Chemotherapy
Radiotherapy
AstraZeneca
Phase 3
Lymphoma
#NCT06717347
B cell lymphoma
Large B cell lymphoma
None
Treated / Controled
None
Systemic Treatment-Naive
Centre hospitalier universitaire François Mitterrand (Dijon)
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT05920356
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
KRAS G12C
PDL1 Negative (< 1%)
None
Systemic Treatment-Naive
Targeted therapy
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Centre Hospitalier Universitaire de Besançon (Besançon)
Amgen
Phase 3
Stomach and esophageal cancer
#NCT06346392
Stomach
Oesogastric junction
Esophagus
Adenocarcinoma
Locally Advanced
Metastatic
Claudin 18.2
1
2
3 or more
Chemotherapy
HER2
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Besançon (Besançon)
AstraZeneca
Phase 3
Lung cancer
#NCT05555732
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
None
Systemic Treatment-Naive
Immunotherapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Immunotherapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Centre Hospitalier Universitaire de Besançon (Besançon)
Daiichi Sankyo